Automate Your Wheel Strategy on MRNA
With Tiblio's Option Bot, you can configure your own wheel strategy including MRNA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRNA
- Rev/Share 5.6949
- Book/Share 23.9231
- PB 1.4129
- Debt/Equity 0.0735
- CurrentRatio 3.925
- ROIC -0.3274
- MktCap 13204545039.0
- FreeCF/Share -6.8026
- PFCF -4.9772
- PE -4.2304
- Debt/Assets 0.0565
- DivYield 0
- ROE -0.314
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | MRNA | Jefferies | -- | Hold | -- | $30 | Dec. 12, 2025 |
| Initiation | MRNA | Citigroup | -- | Neutral | -- | $40 | March 13, 2025 |
| Downgrade | MRNA | Barclays | Overweight | Equal Weight | $111 | $45 | Feb. 18, 2025 |
| Downgrade | MRNA | Goldman | Buy | Neutral | $99 | $51 | Jan. 29, 2025 |
| Downgrade | MRNA | Argus | Buy | Hold | -- | -- | Dec. 18, 2024 |
| Resumed | MRNA | BofA Securities | -- | Underperform | -- | $41 | Dec. 10, 2024 |
| Initiation | MRNA | Bernstein | -- | Market Perform | -- | $55 | Oct. 17, 2024 |
| Downgrade | MRNA | Jefferies | Buy | Hold | $120 | $65 | Sept. 13, 2024 |
| Downgrade | MRNA | JP Morgan | Neutral | Underweight | $88 | $70 | Sept. 13, 2024 |
| Downgrade | MRNA | Oppenheimer | Outperform | Perform | -- | -- | Sept. 13, 2024 |
News
MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
Moderna secures up to $54.3 million from CEPI to fund a pivotal phase III study of its mRNA-based H5 pandemic flu vaccine candidate, mRNA-1018.
Read More
CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive
CHMP backs EU approval of Moderna's next-generation mNexspike COVID-19 vaccine, with a final European Commission decision expected shortly.
Read More
Moderna 2026 Covid and RSV growth not enough to boost stock, Jefferies says
Published: December 12, 2025 by: Proactive Investors
Sentiment: Negative
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) has been awarded a ‘Hold' rating and $30 price target, implying limited upside, from Jefferies analysts in their initial coverage of the drugmaker. Moderna shares are down almost 28% in the year to date, trading just shy of $30 on Friday morning.
Read More
Moderna (MRNA) Recently Broke Out Above the 50-Day Moving Average
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Moderna (MRNA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MRNA broke through the 50-day moving average, which suggests a short-term bullish trend.
Read More
Moderna (MRNA) Just Reclaimed the 200-Day Moving Average
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Positive
From a technical perspective, Moderna (MRNA) is looking like an interesting pick, as it just reached a key level of support. MRNA recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
Read More
Moderna (MRNA) Recently Broke Out Above the 20-Day Moving Average
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Moderna (MRNA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, MRNA crossed above the 20-day moving average, suggesting a short-term bullish trend.
Read More
Moderna, Inc. (MRNA) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Published: December 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Moderna, Inc. (MRNA) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Read More
Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules
Published: December 02, 2025 by: Zacks Investment Research
Sentiment: Negative
Shares of vaccine makers slide as an internal FDA memo on vaccine safety and plans for stricter rules spark broad pressure across the overall industry.
Read More
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
Published: December 01, 2025 by: Investopedia
Sentiment: Neutral
A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.
Read More
Top Stock Movers Now: Coinbase, Robinhood, Moderna, Synopsys, and More
Published: December 01, 2025 by: Investopedia
Sentiment: Negative
Major U.S. equities indexes lost ground Monday afternoon, as shares of tech and cryptocurrency-related companies pulled back. The S&P 500 and Nasdaq slid about 0.2%, while the Dow dropped 0.4%.
Read More
Moderna stock slides as FDA moves to tighten vaccine guidelines
Published: December 01, 2025 by: Proactive Investors
Sentiment: Negative
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) stock fell sharply on the news that the Food and Drug Administration (FDA) plans to implement stricter approval requirements for vaccines. The announcement raised investor concerns about potential delays and increased scrutiny for the company's pipeline of new products.
Read More
Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men
Published: December 01, 2025 by: Market Watch
Sentiment: Negative
Memo also reportedly mentions vaccines for flu and pneumonia.
Read More
Moderna to Present at Upcoming Piper Sandler's 37th Annual Healthcare Conference on December 2, 2025
Published: November 18, 2025 by: Accesswire
Sentiment: Neutral
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / November 18, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Piper Sandler's 37th Annual Healthcare Conference, on Tuesday, December 2nd at 11:00am ET A live webcast of each of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website. investors.modernatx.com.
Read More
What Is Going On With Moderna Stock?
Published: November 13, 2025 by: Forbes
Sentiment: Positive
Moderna (MRNA) stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return. The company's value has increased by approximately $1.2 billion over the last 5 days, leading to a current market capitalization of around $10 billion.
Read More
Moderna, Inc. (MRNA) Q3 2025 Earnings Call Transcript
Published: November 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Moderna, Inc. ( MRNA ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Lavina Talukdar - Senior VP & Head of Investor Relations Stéphane Bancel - CEO & Director James Mock - Chief Financial Officer Stephen Hoge - President Conference Call Participants Salveen Richter - Goldman Sachs Group, Inc., Research Division Huidong Wang - Barclays Bank PLC, Research Division Cory Kasimov - Evercore ISI Institutional Equities, Research Division Luca Issi - RBC Capital Markets, Research Division Gregory Wiessner - TD Cowen, Research Division Geoffrey Meacham Courtney Breen - Sanford C. Bernstein & Co., LLC.
Read More
Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Moderna MRNA incurred a loss of 51 cents per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $2.15. In the year-ago period, the company had reported earnings per share (EPS) of 3 cents.
Read More
Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Moderna (MRNA) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $2.15. This compares to earnings of $0.03 per share a year ago.
Read More
Should You Buy Moderna Stock Ahead of Q3 Earnings Report?
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Negative
MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.
Read More
Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.
Read More
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Negative
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Moderna (MRNA) Outperforms Broader Market: What You Need to Know
Published: October 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Moderna (MRNA) reached $26.74 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.
Read More
Moderna Named a Top Employer by Science for Eleventh Consecutive Year
Published: October 23, 2025 by: Accesswire
Sentiment: Neutral
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2025 Top Employers Survey for the eleventh consecutive year. Moderna was recognized for its commitment to continuous innovation and a culture that reflects the values of its employees.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Moderna (MRNA) Beats Stock Market Upswing: What Investors Need to Know
Published: October 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Moderna (MRNA) concluded the recent trading session at $28.38, signifying a +2.83% move from its prior day's close.
Read More
3 Of My Favorite Biotech Stocks Under $10
Published: September 29, 2025 by: Seeking Alpha
Sentiment: Positive
Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited for consistent covered call trades. Covered call strategies offer downside protection in the underperforming, high-beta biotech sector, supporting a rinse, wash, and repeat approach.
Read More
Moderna, Inc. (MRNA) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript
Published: September 25, 2025 by: Seeking Alpha
Sentiment: Neutral
Moderna, Inc. (NASDAQ:MRNA ) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 25, 2025 10:30 AM EDT Company Participants Rose Loughlin - Executive Vice President of Research Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.
Read More
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories
Published: September 19, 2025 by: Accesswire
Sentiment: Neutral
CAMBRIDGE, MA / ACCESS Newswire / September 19, 2025 / Moderna announced today that the first mRNA vaccines fully manufactured in Canada are being shipped to provinces and territories. This milestone advances Canada's domestic vaccine production capacity and strengthens national health security.
Read More
Mizuho's Jared Holz: There's not much value left in vaccine stocks
Published: September 19, 2025 by: CNBC Television
Sentiment: Negative
Jared Holz, Mizuho healthcare senior strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on pharmaceuticals, what new government vaccine panel recommendations mean for the stocks, and much more.
Read More
MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response
Published: September 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Moderna jumps after its updated formulation of Spikevax shows an over 8-fold increase in neutralizing antibodies against the LP.8.1 COVID-19 variant in phase IV study.
Read More
MRNA Stock vs. PFE & ALNY
Published: September 15, 2025 by: Forbes
Sentiment: Negative
On Friday, MRNA stock dropped 7% following a report from The Washington Post that stated a group of health officials reportedly used the Vaccine Adverse Event Reporting System to link the deaths of 25 children to COVID-19 vaccines. This drop brings the stock's year-to-date decline to almost 45%.
Read More
About Moderna, Inc. (MRNA)
- IPO Date 2018-12-07
- Website https://www.modernatx.com
- Industry Biotechnology
- CEO Stéphane Bancel
- Employees 5800